Influence of genes suppressing interferon effects in peripheral blood mononuclear cells during triple antiviral therapy for chronic hepatitis C

The levels of expression of interferon-stimulated genes (ISGs) in liver are associated with response to treatment with pegylated interferon (PEG-IFN) plus ribavirin (RBV). However, associations between the responses of ISGs to IFN-based therapy and treatment efficacy or interleukin-28B (IL28B) genot...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2015-02, Vol.10 (2), p.e0118000
Main Authors: Iijima, Sayuki, Matsuura, Kentaro, Watanabe, Tsunamasa, Onomoto, Koji, Fujita, Takashi, Ito, Kyoko, Iio, Etsuko, Miyaki, Tomokatsu, Fujiwara, Kei, Shinkai, Noboru, Kusakabe, Atsunori, Endo, Mio, Nojiri, Shunsuke, Joh, Takashi, Tanaka, Yasuhito
Format: Article
Language:English
Subjects:
Adult
Aged
Antiviral activity
Antiviral agents
Antiviral Agents - therapeutic use
Antiviral drugs
Blood
Cytokines
Dendritic cells
Drug dosages
Drug Therapy, Combination
Female
Gastroenterology
Gene expression
Gene Expression - drug effects
Genes
Genotype
Genotype & phenotype
Genotypes
Hepacivirus - drug effects
Hepacivirus - genetics
Hepatitis
Hepatitis C
Hepatitis C, Chronic - blood
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - genetics
Hepatology
Hospitals
Humans
Infections
Interferon
Interferon regulatory factor 1
Interferon-alpha - therapeutic use
Interferons
Interleukins
Interleukins - genetics
Kinases
Laboratories
Leukocytes (mononuclear)
Leukocytes, Mononuclear - drug effects
Leukocytes, Mononuclear - metabolism
Liver
Male
Metabolism
Middle Aged
mRNA
Patients
Peripheral blood mononuclear cells
Polyethylene Glycols - therapeutic use
Polymorphism, Single Nucleotide
Prospective Studies
Proteinase inhibitors
Real-Time Polymerase Chain Reaction
Recombinant Proteins - therapeutic use
Regulation
Ribavirin
Ribavirin - therapeutic use
Signal transduction
Suppressor of Cytokine Signaling Proteins - genetics
Therapy
Treatment Outcome
University graduates
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The levels of expression of interferon-stimulated genes (ISGs) in liver are associated with response to treatment with pegylated interferon (PEG-IFN) plus ribavirin (RBV). However, associations between the responses of ISGs to IFN-based therapy and treatment efficacy or interleukin-28B (IL28B) genotype have not yet been determined. Therefore, we investigated the early responses of ISGs and interferon-lambdas (IFN-λs) in peripheral blood mononuclear cells (PBMCs) during PEG-IFN/RBV plus NS3/4 protease inhibitor (PI) therapy. We prospectively enrolled 50 chronic hepatitis C patients with HCV genotype 1, and collected PBMCs at baseline, 8 and 24 h after the initial administration of PEG-IFN/RBV/PI. Levels of mRNAs for selected ISGs and IFN-λs were evaluated by real-time PCR. All 31 patients with a favorable IL28B genotype and 13 of 19 with an unfavorable genotype achieved sustained virological responses (SVR). Levels of mRNA for A20, SOCS1, and SOCS3, known to suppress antiviral activity by interfering with the IFN signaling pathway, as well as IRF1 were significantly higher at 8 h in patients with an unfavorable IL28B genotype than in those with a favorable one (P = 0.007, 0.026, 0.0004, 0.0006, respectively), especially in the non-SVR group. Particularly, the fold-change of IRF1 at 8 h relative to baseline was significantly higher in non-SVR than in SVR cases with an unfavorable IL28B genotype (P = 0.035). In conclusion, levels of several mRNAs of genes suppressing antiviral activity in PBMCs during PEG-IFN/RBV/PI differed according to IL28B genotypes, paralleling treatment efficacy.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0118000